Corrales Izquierdo
Fernando Corrales Izquierdo, Pamplona ES
Fernando Corrales Izquierdo, Navarra ES
Patent application number | Description | Published |
---|---|---|
20090042831 | USE OF 5'-METHYLTHIOADENOSINE (MTA) IN THE PREVENTION AND/OR TREATMENT OF AUTOIMMUNE DISEASES AND/OR TRANSPLANT REJECTION - 5′-methylthioadenosine (MTA), its pharmaceutically acceptable salts and/or prodrugs may be used in the prevention and/or treatment of autoimmune diseases, such as, for example, Multiple Sclerosis (MS), as well as in the prevention and/or treatment of transplant rejection. | 02-12-2009 |
20090117591 | Fibrosis Markers - The invention relates to the use of a combination of at least two markers that are selected from among Uromodulin, MAC2BP, AGP1 and Cathepsin A, for the in vitro detection of fibrotic alterations. In addition, the invention relates to a kit for determining the levels of said markers in a biological sample. | 05-07-2009 |
Fernando José Corrales Izquierdo, Pamplona - Navarra ES
Patent application number | Description | Published |
---|---|---|
20110015132 | SYNERGISTIC 5'-METHYLTHIOADENOSINE COMBINATIONS - The present invention relates to combinations of 5′-methylthioadenosine and glatiramer acetate, and to their use in the treatment of multiple sclerosis. In a particular embodiment, the present invention relates to a product comprising 5′-methylthioadenosine and glatiramer acetate as a combined preparation for the simultaneous, separate, or sequential use thereof for the prevention and/or treatment of multiple sclerosis. | 01-20-2011 |
Fernando José Corrales Izquierdo, Pamplona - Navarra ES
Patent application number | Description | Published |
---|---|---|
20110015132 | SYNERGISTIC 5'-METHYLTHIOADENOSINE COMBINATIONS - The present invention relates to combinations of 5′-methylthioadenosine and glatiramer acetate, and to their use in the treatment of multiple sclerosis. In a particular embodiment, the present invention relates to a product comprising 5′-methylthioadenosine and glatiramer acetate as a combined preparation for the simultaneous, separate, or sequential use thereof for the prevention and/or treatment of multiple sclerosis. | 01-20-2011 |
20120220546 | COMPOSTIONS DESIGNED FOR THE INHIBITION AND/OR BLOCKING OF THE EPITHELIAL/MESENCHYMAL TRANSITION - 5′-methylthioadenosine (MTA) is described as a compound that is susceptible to inhibiting and/or blocking the epithelial-mesenchymal transition (EMT), a process whereby epithelial cells become mesenchymal cells. | 08-30-2012 |